Murad Alturkustani1,2,3, Lee-Cyn Ang2,3. 1. Department of Pathology, Faculty of Medicine, King Abdulaziz University Jeddah, Saudi Arabia. 2. London Health Sciences Centre (LHSC) London, ON, Canada. 3. Western University London, ON, Canada.
Abstract
OBJECTIVES: The white matter ischemic changes described in the literature are not specific and include white matter rarefaction, axonal damage, myelin degeneration, astrocytic fragmentation and beading of its processes (clasmatodendrosis), oligodendrocyte loss, and microglial activation. This morphological spectrum overlaps with morphological features of many other conditions. This retrospective study aims to describe the cellular changes (using immunohistochemical studies) in a spectrum of ischemic leukoencephalopathy. METHODS: We studied 24 white matter ischemic injury cases with a well-documented interval from the ischemic event of interest. The autopsy reports were reviewed for the clinical information and pathological features to select the most representative areas for other stains and immunostains: luxol fast blue with hematoxylin and eosin (LFB-HE), anti-amyloid precursor protein (APP), anti-glial fibrillary acidic protein (GFAP), and anti-human leukocyte antigen (HLA-DR) antibodies. RESULTS: The early changes detected in mild injury were axonal staining highlighted by APP immunostain and astrocytic and microglial reaction with no significant cellular loss. The most severe injury may lead to losing almost all cellular elements (complete infarct) and replacement by macrophages with time. Injuries in between resulted in a morphological spectrum of selective cellular injury (incomplete infarct), including apoptotic nuclei, axonal staining and swellings, clasmatodendrosis, and loss of ramified microglia. CONCLUSIONS: The pathological findings suggested that widespread axonal staining and swellings are early features followed or accompanied by loss of HLA-DR positive ramified microglia and then by astrocytes in ischemic leukoencephalopathy. The awareness of this morphological spectrum would prevent misdiagnosis, provide a better understanding of this condition and can guide future studies on this important and common subject. AJTR
OBJECTIVES: The white matter ischemic changes described in the literature are not specific and include white matter rarefaction, axonal damage, myelin degeneration, astrocytic fragmentation and beading of its processes (clasmatodendrosis), oligodendrocyte loss, and microglial activation. This morphological spectrum overlaps with morphological features of many other conditions. This retrospective study aims to describe the cellular changes (using immunohistochemical studies) in a spectrum of ischemic leukoencephalopathy. METHODS: We studied 24 white matter ischemic injury cases with a well-documented interval from the ischemic event of interest. The autopsy reports were reviewed for the clinical information and pathological features to select the most representative areas for other stains and immunostains: luxol fast blue with hematoxylin and eosin (LFB-HE), anti-amyloid precursor protein (APP), anti-glial fibrillary acidic protein (GFAP), and anti-human leukocyte antigen (HLA-DR) antibodies. RESULTS: The early changes detected in mild injury were axonal staining highlighted by APP immunostain and astrocytic and microglial reaction with no significant cellular loss. The most severe injury may lead to losing almost all cellular elements (complete infarct) and replacement by macrophages with time. Injuries in between resulted in a morphological spectrum of selective cellular injury (incomplete infarct), including apoptotic nuclei, axonal staining and swellings, clasmatodendrosis, and loss of ramified microglia. CONCLUSIONS: The pathological findings suggested that widespread axonal staining and swellings are early features followed or accompanied by loss of HLA-DR positive ramified microglia and then by astrocytes in ischemic leukoencephalopathy. The awareness of this morphological spectrum would prevent misdiagnosis, provide a better understanding of this condition and can guide future studies on this important and common subject. AJTR
Authors: Antonio L E Falcao; David C Reutens; Romesh Markus; Masatoshi Koga; Stephen J Read; Henri Tochon-Danguy; John Sachinidis; David W Howells; Geoffrey A Donnan Journal: Ann Neurol Date: 2004-11 Impact factor: 10.422
Authors: Alida A Gouw; Alexandra Seewann; Wiesje M van der Flier; Frederik Barkhof; Annemieke M Rozemuller; Philip Scheltens; Jeroen J G Geurts Journal: J Neurol Neurosurg Psychiatry Date: 2010-10-09 Impact factor: 10.154
Authors: Daniel F Marker; Julia K Kofler; Joseph A Mettenburg; Mounzer E Agha; Clayton A Wiley Journal: J Neuropathol Exp Neurol Date: 2020-10-01 Impact factor: 3.685
Authors: Tarek Sharshar; Françoise Gray; Frédéric Poron; Jean Claude Raphael; Philippe Gajdos; Djillali Annane Journal: Crit Care Med Date: 2002-10 Impact factor: 7.598